Anavex/$AVXL

13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1Y5YMAX

About Anavex

Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are further used in the analysis of clinical trials. The company's focus is on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its various therapeutic candidates in different stages of development include Anavex 2-73 (Blacamesine), Anavex 3-71 (AF710B), Anavex 1-41, and Anavex 1066.

Ticker

$AVXL
Primary listing

Industry

Biotechnology

Employees

42

ISIN

US0327973006

Anavex Metrics

BasicAdvanced
$902M
-
-$0.56
0.82
-

What the Analysts think about Anavex

Analyst ratings (Buy, Hold, Sell) for Anavex stock.

Bulls say / Bears say

Anavex Life Sciences reported a quarterly loss of $0.14 per share, beating estimates by $0.03, indicating better-than-expected financial performance. (nasdaq.com)
Institutional investors like Nwam LLC and Charles Schwab Investment Management Inc. have increased their holdings in Anavex, reflecting confidence in the company's prospects. (etfdailynews.com)
Analysts from D. Boral Capital and HC Wainwright have reiterated 'buy' ratings for Anavex, with target prices of $46.00 and $40.00 respectively, suggesting strong growth potential. (etfdailynews.com)
Anavex shares dropped 33% after providing an update on its Rett Syndrome program, raising concerns about the program's progress. (benzinga.com)
Jane Street Group LLC reduced its stake in Anavex by 65.7%, potentially indicating a lack of confidence among some institutional investors. (americanbankingnews.com)
Anavex reported a fiscal first-quarter loss of $12.1 million, highlighting ongoing financial challenges. (thetelegraph.com)
Data summarised monthly by Lightyear AI. Last updated on 4 Jun 2025.

Anavex Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Anavex Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $AVXL

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs